- Clearmind Medicine (MND) and SciSparc (SPRC) yield positive results for their Psychedelic Combination Treatment
- The evaluation was for Clearmind’s proprietary psychedelic molecule, MEAI and SciSparc’s CannAmide™ for treating alcohol consumption
- The severity of impairments was scored on a five-point scale by a qualified blinded toxicologist
- Results from this test showed a high safety profile of the combination treatment with no treatment-related changes observed
- The mice were provided with 20 per cent alcohol solution for 24 hours, three times a week for seven weeks
- Clearmind Medicine (MND) is up 1.33 per cent, trading at C$0.38 at 11:37 am ET
Clearmind Medicine (MND) has released favourable safety profile results from its joint pre-clinical trial with SciSparc Ltd. (NASDAQ: SPRC).
The trial evaluated the combination of Clearmind’s proprietary psychedelic molecule MEAI and SciSparc’s CannAmide™ for treating alcohol consumption.
“We are extremely pleased with these positive results that strengthen our belief in the potential of our novel propriety psychedelic molecule MEAI,” said Dr. Adi Zuloff- Shani, Clearmind’s Chief Executive Officer.
“We plan to explore further the safety and efficacy of combining our novel technology with Clearmind’s novel molecule,” added Dr. Zuloff-Shani.
Earlier trials successfully showed a significant dose-dependent effect for MEAI treatment in reducing alcohol consumption in mice. Another impactful achievement happened when combining CannAmide™ with a lower sub-effective MEAI dose.
Positive results follow previously announced results which showed that alcohol consumption was significantly reduced following treatment with MEAI at a dose of 40 mg/kg and higher (p<0.01).
A histopathology assessment was conducted– a study of disease-related issues–to determine the safety of the proprietary combination of MEAI and CannAmide vs. control (mice not exposed to alcohol).
Several organs (heart, lungs, liver, kidneys, brain, pancreas, spleen, and thyroid gland) were harvested and included an evaluation for impairment.
A qualified blinded toxicologist scored the severity of impairments on a five-point scale. This test showed a high safety profile of the combination treatment with no treatment-related changes observed.
Alcohol consumption was significantly reduced following dual treatment with 25 mg/kg CannAmide™ in addition to MEAI at a dose of 20 mg/kg and compared to consumption before treatment.
The mice were provided with 20 per cent alcohol solution for 24 hours, three times a week for seven weeks, and were treated every day during the last two weeks of alcohol treatment.
The alcohol consumption was measured by weighing the alcohol bottles before and after; water consumption was measured similarly.
Clearmind is a biotech company focused on discovering and developing novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder, binge eating, and depression.
It holds several patents for the non-hallucinogenic compound MEAI.
The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding acquiring other intellectual property to build its portfolio.
Clearmind Medicine (MND) is up 1.33 per cent, trading at C$0.38 at 11:37 am ET.
